[go: up one dir, main page]

MX394766B - Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. - Google Patents

Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.

Info

Publication number
MX394766B
MX394766B MX2018013873A MX2018013873A MX394766B MX 394766 B MX394766 B MX 394766B MX 2018013873 A MX2018013873 A MX 2018013873A MX 2018013873 A MX2018013873 A MX 2018013873A MX 394766 B MX394766 B MX 394766B
Authority
MX
Mexico
Prior art keywords
treatment
irinotecan
lung cancer
small cell
cell lung
Prior art date
Application number
MX2018013873A
Other languages
English (en)
Other versions
MX2018013873A (es
Inventor
Bambang Adiwijaya
Helen Lee
Jonathan Basil Fitzgerald
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of MX2018013873A publication Critical patent/MX2018013873A/es
Publication of MX394766B publication Critical patent/MX394766B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nuevas terapias para el tratamiento del cáncer de pulmón de células pequeñas (SCLC) que incluyen la administración de un tratamiento antineoplásico que consiste de irinotecán liposomal administrado una vez cada dos semanas, que incluye opcionalmente la administración de otros agentes no antineoplásicos al paciente, tal como la administración de un corticosteroide y un antiemético al paciente antes de la administración del liposoma de irinotecán.
MX2018013873A 2016-05-18 2017-05-17 Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. MX394766B (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201662337961P 2016-05-18 2016-05-18
US201662345178P 2016-06-03 2016-06-03
US201662362735P 2016-07-15 2016-07-15
US201662370449P 2016-08-03 2016-08-03
US201662394870P 2016-09-15 2016-09-15
US201662414050P 2016-10-28 2016-10-28
US201662415821P 2016-11-01 2016-11-01
US201662422807P 2016-11-16 2016-11-16
US201662433925P 2016-12-14 2016-12-14
US201762455823P 2017-02-07 2017-02-07
US201762474661P 2017-03-22 2017-03-22
PCT/IB2017/000681 WO2017199093A1 (en) 2016-05-18 2017-05-17 Nanoliposomal irinotecan for use in treating small cell lung cancer

Publications (2)

Publication Number Publication Date
MX2018013873A MX2018013873A (es) 2019-02-14
MX394766B true MX394766B (es) 2025-03-24

Family

ID=59258274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013873A MX394766B (es) 2016-05-18 2017-05-17 Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.

Country Status (16)

Country Link
US (1) US20230000858A1 (es)
EP (1) EP3458059A1 (es)
JP (3) JP2019516693A (es)
KR (1) KR20190009319A (es)
CN (1) CN109640995A (es)
AU (1) AU2017267449A1 (es)
BR (1) BR112018072988A2 (es)
CA (1) CA3023743A1 (es)
IL (1) IL262656A (es)
MA (1) MA45046A (es)
MX (1) MX394766B (es)
PH (1) PH12018502422A1 (es)
SG (2) SG11201809788VA (es)
TW (1) TWI791437B (es)
UA (1) UA125646C2 (es)
WO (1) WO2017199093A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
KR20190077441A (ko) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 리포솜성 이리노테칸, 옥살리플라틴, 5-플루오로우라실 (및 류코보린)을 포함하는 조합 요법을 사용하는 위암 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967961T3 (es) * 2004-05-03 2024-05-06 Ipsen Biopharm Ltd Liposomas útiles en la administración de fármacos
EP2187869B1 (en) * 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Also Published As

Publication number Publication date
TWI791437B (zh) 2023-02-11
AU2017267449A1 (en) 2018-11-15
TW201740946A (zh) 2017-12-01
MX2018013873A (es) 2019-02-14
JP2020117548A (ja) 2020-08-06
SG11201809788VA (en) 2018-12-28
US20230000858A1 (en) 2023-01-05
PH12018502422A1 (en) 2019-03-11
IL262656A (en) 2018-12-31
SG10201912407YA (en) 2020-02-27
BR112018072988A2 (pt) 2019-04-09
MA45046A (fr) 2019-03-27
EP3458059A1 (en) 2019-03-27
CA3023743A1 (en) 2017-11-23
UA125646C2 (uk) 2022-05-11
CN109640995A (zh) 2019-04-16
JP2019516693A (ja) 2019-06-20
JP2022010295A (ja) 2022-01-14
KR20190009319A (ko) 2019-01-28
WO2017199093A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX394766B (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
ECSP17048849A (es) Terapias de combinación para el tratamiento de cánceres
MX392408B (es) Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina).
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX385425B (es) Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2017015532A (es) Terapia de combinacion pac-1.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX383682B (es) Tratamiento para cancer de mama usando una combinación de una formulación liposomal catiónica de taxano, una formulación no liposomal de taxano y un agente activo adicional.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
EA201892592A1 (ru) Лечение мелкоклеточного рака легких с помощью липосомального иринотекана
DOP2017000174A (es) Terapias de combinación para el tratamiento de cánceres
HK1242199A1 (en) Treatment of cancer using tlr9 agonist with checkpoint inhibitors
AR106220A1 (es) Conjugados homogéneos específicos de sitio con inhibidores de ksp
AR078798A1 (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona